DCGI Gives Nod to Bharat Biotech's Intranasal COVID Vaccine for Restricted Emergency Use

"Being an intranasal vaccine, BBV154 may produce local antibodies in the upper respiratory tract. These may provide the potential to reduce infection and transmission. Further studies are being planned," the firm said.

Related Keywords

India ,New Delhi ,Delhi ,Bharat ,Narendra Modi ,Sabka Prayas ,Mansukh Mandaviya ,Bharat Biotech International Limited ,Drugs Controller General ,Bharat Biotech ,Fight Against ,Chimpanzee Adenovirus Vectored ,Prime Minister Narendra Modi ,Covaxin ,Covaxin Nasal Vaccine ,Covishield ,Dcgi ,Drugs Controller General Of India ,Intranasal Covid 19 Vaccine ,Intranasal Covid Vaccine ,Nasal Covid 19 Vaccine ,Nasal Vaccine ,